Drug intelligence / Profile preview

Bio-R

Development stage: Unknown
Lead developer: Kaiser Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Bio-R (also known as Bio-RD) is a branded generic pharmaceutical product developed and marketed by Kaiser Pharmaceuticals. It contains domperidone as its active ingredient, which is a small molecule dopamine D2 receptor antagonist. Domperidone works by blocking dopamine receptors in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) located in the area postrema. Because it does not readily cross the blood-brain barrier, it primarily exerts peripheral effects, such as increasing gastrointestinal motility and gastric emptying, while providing antiemetic relief. It is used to treat nausea, vomiting, and gastrointestinal motility disorders.

Brand names: Bio-RBio-RD
Other names: domperidone

Targets

DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on Bio-R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio-R.

Explore the full profile